Cipla LtdNSE: CIPLA

Press Release Jun 15 2021

· Issued by Cipla Ltd

Filed with NSE · · 3 pages · English

Summary by 6ix AI

It informs stakeholders about Avenue's receipt of a Complete Response Letter from the FDA concerning IV tramadol. The letter indicates that the FDA does not support the drug's approval as a monotherapy for acute pain treatment.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Cipla Ltd on 6ix

Earlier from Cipla

Later from Cipla

All Cipla news releases